Empresas y finanzas

Sorin Group Announces Successful First Human Implant of Uniquely-Designed Heart Valve Suitable for Percutaneous Procedures



    The Sorin Group (MIL:SRN), a world leader in technologies for the
    treatment of cardiovascular diseases, announces the successful implant
    of its first uniquely-designed heart valve suitable for percutaneous
    procedures. The implant was performed by Prof. Axel Haverich and his
    team at Medizinische Hochschule in Hannover, Germany. The 78-year-old
    patient, who was suffering from aortic heart valve stenosis, has
    already left intensive care and is recovering normally, according to
    his physicians.

    "The ease with which the valve was implanted, without any use of
    sutures, allows for significant reduction in procedure time and
    corresponding patient risk," commented Prof. Haverich.

    Thanks to its unique design - in which the securing structure is
    independent from the valve-supporting system -, the valve is
    self-securing and is in no way put under any stress, therefore
    overcoming the primary defects of other minimally-invasive valves
    currently being tested.

    The success behind Sorin's heart valve lies in the Group's
    in-house competencies in stent research and development as well as its
    historic prominence in heart-valve development and production. The
    characteristics of the securing stent and the flexibility of the valve
    are designed to ensure optimal sealing and prevent perivalvular
    leakage, breaking new ground in the evolution of heart valves.

    The particular biological valve itself used as part of "Sorin's
    Percutaneous Heart Valve Project" has a proven track record for its
    hemodynamic profile, reliability and durability over the past two
    decades and has never had any structural failures since it has been in
    use. Sorin is the only company in the world to use a heart valve that
    has been proven and accepted by the medical community worldwide in
    this particular context.

    "Only the Sorin Group has the in-house know-how and strong
    tradition in research and development to create such a unique heart
    valve," said Drago Cerchiari, Sorin Group Chief Executive Officer. "We
    look forward to continuing to achieve our ultimate goal of offering
    high-quality, less invasive, life-saving medical technology and
    procedures across the globe."

    About the Sorin Group

    The Sorin Group (Bloomberg: SRN.IM; Reuters: SORN.MI), a world
    leader in the development of medical technologies for cardiac surgery,
    offers innovative therapies for cardiac rhythm dysfunctions,
    interventional cardiology and the treatment of chronic kidney
    diseases. The Sorin Group includes: Dideco, CarboMedics, Inc., COBE
    Cardiovascular, Inc., Stockert, Mitroflow, ELA Medical, Inc., Sorin
    Biomedica, Bellco and Soludia. It has more than 4,500 employees
    working at facilities in more than 80 countries throughout the world
    to serve over 5,000 public and private treatment centers. For more
    information, please visit: www.sorin.com